MedWatch

Impact of China's drug policy will be visible soon, says Jefferies

The first tenders under the new drug program on China's insulin market are expected in late November and early December. The impact of said program is anticipated to be seen around the New Year, and implementation is slated for early 2022, according to the US-based bank Jefferies.

Photo: Tidsvilde Stine/Ritzau Scanpix

China's new drug policy is predicted to have a big impact on Novo Nordisk's insulin sales on the lucrative national market, says the US-based bank Jefferies after a meeting with Novo's Daniel Bohsen, corporate vice president and head of investor relations at the company.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs